VBIO — Valion Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1787740 ·
Last close
$0.17
Market Cap
$689.1K
52W High
$1.30
52W Low
$0.11
ADV30
17,429,717
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,634,000 | -6,202,000 | 38,215,000 | 7,215,000 | 27,153,000 |
| Dec 2025 | -302,000 | — | -1,975,000 | -2,849,000 | 31,607,000 | 12,645,000 | 14,810,000 |
| Sep 2025 | 146,000 | -145,000 | -2,483,000 | -2,596,000 | 6,229,000 | 3,450,000 | 638,000 |
| Jun 2025 | 86,000 | 54,000 | -1,934,000 | -1,931,000 | 4,508,000 | 1,184,000 | 821,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,837,000
Investing CF
$-186,000
Financing CF
$18,221,000
CapEx
$-62,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.91
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-59,034,000
Inventory
$750,000
Receivables
$19,000
ST Investments
—
EBIT TTM
$-11,918,000
Pretax Income TTM
$-12,716,000
Interest Exp TTM
$648,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$-86,000
EBITDA
$-16,536,000
Free Cash Flow
$-8,062,250
Enterprise Value
$18,021,462
Total Cash
$2,108,000
Total Debt
$17,409,000
Shares Out
4,151,259
Trailing EPS
$-7.38
Book Value
$1.02
ROE
-459.5%
ROA
-57.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -7,898,000 | -8,878,000 | 31,607,000 | 14,810,000 | — | -6,999,000 |
| Dec 2024 | 0 | -4,476,000 | -5,655,000 | 2,807,000 | 272,000 | — | -5,725,000 |
| Dec 2023 | 1,176,000 | -8,245,000 | -8,244,000 | 5,157,000 | 1,577,000 | — | -8,511,000 |
| Dec 2022 | 1,840,000 | -10,098,000 | -10,096,000 | 5,875,000 | 2,245,000 | — | -8,919,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZVSA | ZyVersa Therapeutics, Inc. | $805.5K | $0.10 | — |
| RGBPP | Regen BioPharma Inc | $587.3K | $0.00 | — |
| ATXI | AVENUE THERAPEUTICS, INC. | $848.8K | $0.26 | — |
| EVFM | Evofem Biosciences, Inc. | $927.7K | $0.01 | — |
| SKVI | SKINVISIBLE, INC. | $972.7K | $0.18 | — |
News headlines (Yahoo Finance, 1h cache)
Valion Bio Advances Government-Funded Entolimod Radiation Injury Studies With Data Expected in Early Fall
2026-08-12 14:17 · Yahoo
World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market
2026-07-20 17:05 · Yahoo
Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion
2026-07-14 11:45 · Yahoo
AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS
2026-06-25 11:45 · Yahoo
Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase
2026-08-13 14:00 · Yahoo
Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury
2026-08-12 13:29 · Yahoo
Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures
2026-06-11 11:45 · Yahoo
VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME
2026-05-19 20:38 · Yahoo
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform
2026-05-14 20:30 · Yahoo
VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
2026-05-14 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.